On October 28, 2026, the US Department of Health and Human Services announced an enforcement-discretion policy for peptide compounding: while the 503A Bulks List is developed through rulemaking, state-licensed pharmacies, federal facilities, and licensed physicians may compound with certain peptide bulk drug substances without HHS enforcement action. The notice, signed by HHS Secretary Robert F. Kennedy, Jr., was published in the Federal Register on October 30, 2026 as "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (91 FR 68526). The BBC and US News covered the announcement the day it broke, with US News running the version of the story most readers will meet: the health department moving to "allow temporary sale of some unapproved peptides."
The document's own caveats are load-bearing. It is not binding. It establishes no rights. It can be revisited on any safety signal or product-quality issue. And compounded drugs remain unapproved and unreviewed by FDA. What moved is the federal government's enforcement posture toward 503A compounders — not the approval status of any peptide, and not what any individual may lawfully buy. This piece covers what the notice says, where the six-peptide list actually lives, what the policy is not, and what to watch while the comment window is open.
What the notice actually says
The notice announces a policy, not a rule. Under it, state-licensed pharmacies, federal facilities, and licensed physicians may compound with certain peptide bulk drug substances under section 503A of the Food, Drug, and Cosmetic Act without HHS enforcement action, while the 503A Bulks List — the register that determines which bulk substances a compounder may lawfully use — is developed through rulemaking. The Federal Register document is formally a notice of availability: it announces the policy and opens Docket No. HHS-OASH-2026-0496 for comments via regulations.gov until roughly November 13, 2026 — two weeks after publication, per the notice.
One naming note, because coverage uses both labels. The published notice is titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The phrase "Interim Access Policy," used by the OMB review entry and by law-firm coverage, does not appear in the Federal Register text — it says "interim policy" once. Same instrument; the Federal Register title is the canonical one. The policy had sat at OMB since October 14 before the October 28 announcement.
The limits are stated in the notice itself. It is non-binding and establishes no rights. It can be revisited on any safety signal or product-quality issue. And the drugs compounded under it remain unapproved and unreviewed by FDA — the sentence the notice carries and most social-media summaries will drop.
The six peptides — and where the list actually lives
Here is the detail that will surprise anyone who arrived from a headline: the Federal Register notice names no peptides. The covered substances sit in an appendix to the HHS policy document that the notice makes available. Per that document, as consistently reported across independent coverage, six peptide bulk drug substances are covered: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon.
Per early BPC-157 coverage of the policy, the discretion is framed as appropriate for subcutaneous, intramuscular, oral, and topical routes of administration. That is a description of how the policy document frames its own scope. It is not a statement that any particular use of any particular peptide is advisable — a question the notice does not address, and one this explainer does not either.
The six names are not a random draw. They are the same six substances the FDA's Pharmacy Compounding Advisory Committee took up at its July 23–24, 2026 meeting — the meeting at which, as we reported, the committee recommended all six for the 503A Bulks List over the objections of FDA's own review staff, with law-firm analyses putting that rulemaking sequence at 12 to 24 months from acceptance. The enforcement-discretion policy is the bridge across that gap: HHS is telling 503A compounders it will not enforce against these six bulks while the list catches up.
What the policy is not
Three confusions will circulate while the comment window is open, and each deserves its own sentence. The policy is not approval — every compounded drug made under it remains unapproved and unreviewed by FDA. It is not binding — it establishes no rights and can be revisited on any safety signal or product-quality issue. And it is not a statement about what consumers may buy — it addresses who may compound: state-licensed pharmacies, federal facilities, and licensed physicians.
That last distinction is where the story bends most easily. US News framed the announcement as the health department moving to "allow temporary sale of some unapproved peptides" — a consumer-facing reading. The instrument itself is addressed to compounders, not to buyers. The warning letters, prosecutions, and closures cataloged in our peptide vendor tracker belong to a lane this notice does not touch, and the map of what is actually lawful for an individual to buy is a separate question our peptide legal status guide covers.
Reaction split along predictable lines. The BBC and US News covered the announcement on October 28; the Partnership for Safe Medicines published a critical response on November 2; and law-firm advisories through early November — Holland & Knight and Buchanan Ingersoll among them — walked compounding pharmacies through what the interim policy covers. Read one of each: the news coverage, the safety critique, and the compliance advisory describe the same instrument in three different registers.
What to watch
The live item is the comment window. Comments are open via regulations.gov under Docket No. HHS-OASH-2026-0496 until roughly November 13, 2026 — two weeks after publication, per the notice. That is the one dated step in an otherwise open-ended document, and the moment when the public record around the policy gets built. A standing reference page — the HHS 503A peptide policy hub — tracks the milestones and the docket while the window is open.
After the window closes, the story returns to rulemaking. The six substances are not on the 503A Bulks List; the notice exists because that list is developed through rulemaking, and the discretion covers the interim. A proposed rule adding any of the six would start the sequence — proposal, comment period, final rule — through which legal status, not just enforcement posture, actually changes: the distinction this whole story turns on. And the reversion trigger stays live throughout: on its own terms, any safety signal or product-quality issue can end the policy.
BPC-157 and TB-500 are core topics on this site, existing guides cover both, and all six substances have profiles here — linked above. Each milestone in this sequence publishes onto the regulatory timeline as it lands, starting with the July advisory-committee vote that opened it. What does not change, whichever way the rulemaking goes: nothing here is medical advice, and nothing in the notice makes a compounded peptide reviewed, approved, or right for any particular person.